Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Debating science policy

Executive Summary

Merck Director of Global Outcomes Research and HTA Shuvayu Sen is a signatory on "ScienceDebate2008," an effort to promote a presidential debate on science and technology policy. Others endorsing the debate campaign include Lois Quam, formerly president of UnitedHealth's Public and Social Markets Group, University of Pennsylvania Center for Bioethics Director Arthur Caplan, University of Maryland Biotechnology Institute President Jennie Hunter-Cevera and human genome researcher J. Craig Venter. Health policy topics listed by the group include antibiotic resistant bacteria, drug patents and generic drugs, the genome and bioethics...

You may also be interested in...



Rare Disease Advocates Lobby US Congress For FDA Center of Excellence

Number one ask is for congressional pressure to centralize rare disease expertise at the agency, but advocates also are preparing legislation that would mandate the new center.

FDA’s 2021 Budget Priorities For Cosmetics, Food Programs Include AI Use In Postmarket Oversight

FDA’s food, dietary supplement and cosmetics division seeks funding to support its artificial intelligence capabilities, including post-market surveillance and speedy interventions in instances where safety issues arise. Also of note, the agency cites UV filters’ effects on the skin microbiome as a research priority in its fiscal 2021 budget justification to Congress.

Don't Take For Granted A Patient's Role In Clinical Trials, Experts Say

Catering to patients can help make clinical trials more accessible and useful, presenters argued at a recent conference.

UsernamePublicRestriction

Register

PS049257

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel